<DOC>
	<DOCNO>NCT02083679</DOCNO>
	<brief_summary>This multi-center , open-label , Phase 1b , dose escalation trial Sym004 administer combination 1 3 platinum-doublets subject Stage IV Non-Small Cell Lung Cancer ( NSCLC ) . The sponsor decide discontinue development Sym004 . Also decision make discontinue development Sym004 NSCLC indication . The decision discontinue Sym004 NSCLC relate safety efficacy finding regard Sym004 . As result early discontinuation trial dose escalation part , expansion cohort longer perform hence pre-specified secondary endpoint analyze remove protocol base protocol amendment 2 date 31 March 2015 .</brief_summary>
	<brief_title>Sym004 Subjects With Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Male female outpatient ( except inpatient stay require medical need Investigator 's discretion ) least 18 year age time inform consent Histologicallyconfirmed NSCLC Stage IV disease ( accord seventh edition lung cancer stag system ) Eligibility platinumbased chemotherapy Tumor tissue available epidermal growth factor receptor ( EGFR ) expression analysis Measurable disease define 1 target lesion accord Response Evaluation Criteria In Solid Tumors version 1.1 ( RECIST 1.1 ) Life expectancy least 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 1 Other protocol define inclusion criterion could apply Previous therapy Stage IV NSCLC , neo adjuvant chemotherapy chemoradiotherapy within previous 6 month Previous investigational drug anticancer therapy 30 day ( 5 halflives noncytotoxics , whichever short ) prior start trial treatment In country anaplastic lymphoma kinase ( ALK ) inhibitor available treatment NSCLC , subject need screen ALK fusion gene rearrangement exclude positive , unless previously treat progressed appropriate tyrosine kinase inhibitor ( TKI ) therapy In country EGFR TKIs available treatment NSCLC , subject need screen EGFR mutation exclude positive , unless previously treat progressed appropriate TKI therapy Concurrent chronic immunosuppressive hormone anticancer therapy ( except physiologic hormone replacement ) Known brain metastasis ( unless asymptomatic treat ) leptomeningeal metastasis , include suspect leptomeningeal spread positive cytology History malignancy within 5 year ( except basal cell carcinoma skin carcinoma situ cervix ) Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Sym004</keyword>
</DOC>